查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1403502

重症肌無力治療市場至2030年的預測：按類型、藥物類別、治療方式、通路和地區的全球分析

Myasthenia Gravis Disease Treatment Market Forecasts to 2030 - Global Analysis By Type, Drug Class, Treatment Modality, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的資料，2023年全球重症肌無力治療市場規模為 22 億美元，預計在預測期內年複合成長率為 8.5%，到2030年將達到 39 億美元。

重症肌無力（MG）治療市場是指致力於治療重症肌無力的藥物和治療領域，重症肌無力是一種以肌肉無力和疲勞為特徵的慢性自體免疫神經肌肉疾病。該市場包括目的是控制重症肌無力患者症狀，改善神經肌肉傳導和提高整體生活品質的各種醫療干預措施。

根據國家罕見疾病組織（NORD）的資料，美國每 10 萬人中約有 14 至 40 人患有重症肌無力。報告表明，近幾十年來，重症肌無力的發生率一直在增加。這是由於患者識別更加容易以及全球自體自體免疫疾病的盛行率不斷增加。

藥品核准和管道開發

重症肌無力（MG）的治療高度依賴管道開發和藥物核准。新藥的核准提供了更多的治療選擇，填補了市場空白，並改善了患者的治療效果。進行的管道開發有望推進藥物機制並提高療效，表明致力於改進治療方法。此外，這些進展可以為重症肌無力患者制定個體化和有針對性的治療計劃，減少副作用並改善管理。

缺乏疾病修正治療

鑑於自體免疫疾病的複雜性和多因素性質，目前尚無可用於治療重症肌無力（MG）的疾病修正治療。與其他自體自體免疫疾病不同，導致重症肌無力的潛在機制尚未完全了解，這使得標靶治療的開發變得困難。目前大多數治療方法使用乙醯膽鹼酯酶抑制劑和免疫抑制劑來控制症狀，這些藥物可以緩解症狀，但無法解決根本原因。然而，儘管關於 MG 的精確機制和緩解疾病治療方法的開發還有很多知識有待了解，但疾病的複雜性仍然是主要障礙。

聯合治療

聯合治療是很有前景的治療方法，可以解決重症肌無力（MG）的不同方面。乙醯膽鹼酯酶抑制劑和免疫抑制劑（例如皮質類固醇和免疫調節劑）協同作用，可控制 MG 特有的肌肉無力和自體免疫反應。此外，針對特定免疫途徑的新型生物療法可以與傳統的醫療干預措施結合使用。透過解決複雜病理學的不同方面，聯合治療目的是最大限度地提高療效，同時減少與大劑量單藥相關的副作用。

患者反應的差異

重症肌無力患者患有複雜的自體免疫疾病，每個人對治療的反應都不同。治療結果取決於許多因素，包括共病、疾病嚴重程度和遺傳變異。為了解決這個問題，研究精準醫學方法，目的是根據患者的特定特徵量身定做治療方法。然而，製藥公司和醫療專業人士仍然擔心 MG 患者反應的固有變異性，這對市場上現有治療性介入的標準化和最佳化具有影響。

COVID-19 的影響：

醫療保健服務和供應鏈的重大中斷影響患者獲得藥物的機會，其中 COVID-19 已成為重症肌無力（MG）治療市場的一個主要因素。遠端醫療開闢了新的諮詢選擇，但血漿靜脈注射和靜脈注射免疫球蛋白（IVIG）等面對面治療面臨後勤挑戰。此外，大流行的經濟負擔影響患者的負擔能力和醫療預算，也影響了重症肌無力治療的市場。儘管存在這些挑戰，進行的研究和開發舉措仍在繼續探索新的 MG治療方法，以解決當前的障礙和潛在的未來市場動態。

膽鹼酯酶抑制劑細分市場預計將在預測期內成為最大的細分市場

由於膽鹼酯酶抑制劑在治療自體自體免疫神經肌肉疾病症狀的有效性，重症肌無力治療市場正經歷強勁成長。透過阻斷乙醯膽鹼的分解，Pyridostigmine等膽鹼酯酶抑制劑對於改善神經肌肉傳遞非常重要，改善肌肉力量和功能。此外，隨著重症肌無力治療方法的改變以及更多醫療保健提供者將膽鹼酯酶抑制劑涵蓋其綜合治療計劃，預計市場將繼續擴大。

靜脈注射治療領域預計在預測期內年複合成長率最高。

靜脈治療（IVT）因其能夠快速緩解重症肌無力的急性症狀而成為重症肌無力治療市場中不斷成長的區隔。在治療重症肌無力惡化時，靜脈注射可以精確控制劑量並快速傳遞免疫抑制劑，例如靜脈注射免疫球蛋白（IVIG）。在嚴重的情況下，這種治療方法特別有用，因為它需要迅速採取行動來穩定患者的病情。此外，家庭 IVT 和輸液技術便利性的提高為患者提供了更方便、更容易獲得的治療選擇，支持了該細分市場的成長，推動了市場擴張。

佔比最高的地區

由於重症肌無力（MG）盛行率上升、醫療設施改善以及公眾對該疾病的認知不斷提高，重症肌無力（MG）藥物的銷售量在亞太地區顯著增加。該地區活性化的研發活動引進新的治療方案。政府降低醫療保健成本和改善醫療保健可近性的計劃對於促進市場擴張也非常重要。此外，重症肌無力的治療模式不斷變化，亞太地區對個人化醫療和生物技術進步的關注度不斷提高，為這一發展做出了重大貢獻。

年複合成長率最高的地區：

由於新治療方法的推出、意識的提高和醫學研究的改進，歐洲重症肌無力治療市場不斷成長。製藥公司和醫療機構之間的合作促進擴大治療選擇。此外，該地區患者意識的提高和醫療基礎設施的改善推動重症肌無力治療市場的擴張。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多3家公司）
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球重症肌無力治療市場：依類型

  • 全身性重症肌無力
  • 重症肌無力眼科
  • 新生兒短暫性重症肌無力
  • 其他類型

第6章 全球重症肌無力治療市場：依藥物類別

  • 膽鹼酯酶抑制劑
  • 單株抗體
  • 皮質類固醇
  • 免疫抑制劑
  • 靜脈注射免疫球蛋白
  • 其他藥物類別

第7章 全球重症肌無力治療市場：依治療方式

  • 外科手術
  • 點滴療法
  • 其他治療方式

第8章 全球重症肌無力治療市場：依通路

  • 網路藥房
  • 醫院藥房
  • 零售藥房
  • 其他分銷管道

第9章 全球重症肌無力治療市場：依地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 推出新藥類別
  • 業務擴展
  • 其他關鍵策略

第11章 公司簡介

  • AbbVie Inc.
  • Alexion Pharmaceutical Inc.
  • Amyasthenia gravisen inc.
  • Astellas pharma inc.
  • Astrazeneca
  • Avadel Pharmaceuticals plc
  • Bausch Health Companies Inc.
  • Baxter International, Inc.
  • Bayer ag
  • Biogen
  • Bristol-myers squibb
  • CSL Behring
  • Daiichi sankyo co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Gilead sciences inc.
  • Glaxosmithkline plc.
  • Grifols SA
  • Merck & co. Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi
  • Servier laboratories
  • Shire plc
  • Takeda Pharmaceutical Company Limited
  • Teva pharmaceutical industries ltd.
  • Valeant Pharmaceuticals International, Inc.
Product Code: SMRC24727

According to Stratistics MRC, the Global Myasthenia Gravis Treatment Market is accounted for $2.2 billion in 2023 and is expected to reach $3.9 billion by 2030 growing at a CAGR of 8.5% during the forecast period. The Myasthenia Gravis (MG) treatment market refers to the pharmaceutical and therapeutic landscape focused on addressing Myasthenia Gravis, a chronic autoimmune neuromuscular disorder characterized by muscle weakness and fatigue. It encompasses a range of medical interventions aimed at managing symptoms, improving neuromuscular transmission, and enhancing the overall quality of life for individuals with MG.

According to the National Organization for Rare Disorders (NORD), in the U.S., around 14-40 per 100,000 individuals suffer from myasthenia gravis. Reports suggest that the frequency of the disorder is on the rise over the last several decades. This can be attributed to the better identification of patients and the increasing prevalence of autoimmune disorders worldwide.

Market Dynamics:

Driver:

Drug approvals and pipeline developments

Treatment for myasthenia gravis (MG) is largely driven by pipeline advancements and drug approvals. New drug approvals provide more therapeutic options, filling gaps in the market and improving patient outcomes. A dedication to improving treatment modalities with potential advancements in drug mechanisms and increased efficacy is indicated by ongoing pipeline developments. Additionally, these developments could result in more individualized and focused treatment plans for MG patients, reducing side effects, and improving management.

Restraint:

Lack of disease-modifying therapies

Concerning the complex and multifactorial nature of autoimmune disorders, there are currently no disease-modifying therapies available for the treatment of myasthenia gravis (MG). Targeted therapy development is difficult because, unlike some other autoimmune diseases, the underlying mechanisms causing MG are not fully understood. The majority of current therapies use acetylcholinesterase inhibitors and immunosuppression to manage symptoms; they relieve symptoms but do not address the underlying cause. However, though there is still much to learn about the exact mechanisms underlying MG and the development of disease-modifying treatments, the disorder's complexity continues to be a major barrier.

Opportunity:

Combination therapies

Combination therapies provide a promising approach to treating myasthenia gravis (MG) by addressing various aspects of the disease. Acetylcholinesterase inhibitors and immunosuppressive medications, such as corticosteroids or immunomodulators, work in concert to manage MG's characteristic muscle weakness and autoimmune response. Additionally, novel biologic therapies that target particular immune pathways have the potential to be combined with conventional medical interventions. Combination therapies seek to maximize effectiveness while reducing side effects related to high dosages of individual medications by addressing different aspects of the intricate pathophysiology.

Threat:

Variability in patient response

Patients with Myasthenia Gravis have a complex autoimmune disorder, and their responses to therapies vary from person to person. Treatment outcomes vary depending on a number of factors, including comorbidities, disease severity, and genetic variations. To address this issue, precision medicine approaches are being investigated with the goal of customizing treatments based on unique patient characteristics. However, pharmaceutical companies and medical professionals continue to be concerned about the inherent variability in MG patient responses, which has an impact on the standardization and optimization of therapeutic interventions available on the market.

COVID-19 Impact:

Significant disruptions in healthcare services and supply chains have affected patient access to medications, making COVID-19 a major factor in the market for Myasthenia Gravis (MG) treatment. While telemedicine has opened up new consultation options, in-person treatments such as plasma exchange or intravenous immunoglobulin (IVIG) have encountered logistical difficulties. Furthermore, the pandemic's financial burden has affected patient affordability and healthcare budgets, which has affected the market for MG therapies. Not with standing these difficulties, ongoing research and development initiatives keep looking into novel MG treatments that address both present roadblocks and potential future market dynamics.

The cholinesterase inhibitors segment is expected to be the largest during the forecast period

The market for myasthenia gravis treatment has witnessed robust growth in the cholinesterase inhibitors segment because of the drug's effectiveness in treating the symptoms of the autoimmune neuromuscular disease. By stopping the breakdown of acetylcholine, cholinesterase inhibitors like pyridostigmine are essential in improving neuromuscular transmission and, consequently, muscle strength and function. Additionally, the market is expected to continue expanding as myasthenia gravis treatments change and more healthcare providers include cholinesterase inhibitors in all-encompassing treatment plans.

The intravenous therapy segment is expected to have the highest CAGR during the forecast period

Given its ability to quickly alleviate acute symptoms of the disease, intravenous therapy (IVT) has become a growing segment in the market for myasthenia gravis treatment. When it comes to treating Myasthenia gravis exacerbations, intravenous administration enables accurate dosage control and prompt delivery of immunosuppressive drugs like intravenous immunoglobulin (IVIG). In severe cases, this mode of therapy is especially helpful as it guarantees a prompt response in stabilizing patients. Furthermore, the convenience of in-home IVT and improvements in infusion technologies support the growth of this market segment by giving patients a more convenient and accessible treatment option, which in turn propels market expansion.

Region with largest share:

Myasthenia Gravis (MG) treatment sales have increased substantially in the Asia-Pacific region as a result of rising MG prevalence, improving healthcare facilities, and growing public awareness of the condition. New treatment options have been introduced as a result of an increase in research and development activities in the region. Government programs to improve healthcare affordability and accessibility have also been essential in promoting market expansion. Furthermore, the treatment landscape for myasthenia gravis is constantly changing, and the APAC region is a major contributor to this evolution with its growing emphasis on personalized medicine and biotechnology advancements.

Region with highest CAGR:

The European market for myasthenia gravis treatment is constantly growing as a result of new treatments being introduced, raising awareness, and improvements in medical research. The expansion of treatment options are facilitated by partnerships between pharmaceutical companies and healthcare organizations. Additionally, the region's growing patient awareness and improved healthcare infrastructure is propelling the market expansion for myasthenia gravis treatment.

Key players in the market:

Some of the key players in Myasthenia Gravis Treatment market include AbbVie Inc., Alexion Pharmaceutical Inc., Amyasthenia gravisen inc., Astellas pharma inc., Astrazeneca, Avadel Pharmaceuticals plc, Bausch Health Companies Inc., Baxter International, Inc., Bayer ag, Biogen, Bristol-myers squibb, CSL Behring, Daiichi sankyo co. Ltd., F. Hoffmann-La Roche Ltd., Gilead sciences inc., Glaxosmithkline plc., Grifols SA, Merck & co. Inc., Novartis AG, Pfizer, Inc., Sanofi, Servier laboratories, Shire plc, Takeda Pharmaceutical Company Limited, Teva pharmaceutical industries ltd. and Valeant Pharmaceuticals International, Inc.

Key Developments:

In December 2023, GSK announced that the European Commission (EC) has granted marketing authorization to its cancer drug, Jemperli (dostarlimab), for expanded use in primary advanced or recurrent endometrial cancer. The EC has now approved Jemperli in combination with carboplatin and paclitaxel as a frontline treatment for mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced/recurrent endometrial cancer in adult patients who are candidates for systemic therapy.

In December 2023, Moderna and Merck & Co said they have started a late-stage trial of their experimental personalized mRNA cancer treatment in combination with blockbuster drug Keytruda for patients with a type of lung cancer. The therapy, V940, belongs to a class of treatments called m-RNA-based individualized neoantigen therapy (INT) and is tailored for each patient to generate T-cells, a key part of the body's immune response, based on the specific mutational signature of a tumour.

Drug Classes Covered:

  • Cholinesterase Inhibitors
  • Monoclonal Antibodies
  • Corticosteroids
  • Immunosuppressants
  • Intravenous Immunoglobulins
  • Other Drug Classes

Treatment Modalities Covered:

  • Surgery
  • Intravenous Therapy
  • Other Treatment Modalities

Types Covered:

  • Generalized Myasthenia Gravis
  • Ocular Myasthenia Gravis
  • Transient Neonatal Myasthenia Gravis
  • Other Types

Distribution Channels Covered:

  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies
  • Other Distribution Channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Myasthenia Gravis Disease Treatment Market, By Type

  • 5.1 Introduction
  • 5.2 Generalized Myasthenia Gravis
  • 5.3 Ocular Myasthenia Gravis
  • 5.4 Transient Neonatal Myasthenia Gravis
  • 5.5 Other Types

6 Global Myasthenia Gravis Disease Treatment Market, By Drug Class

  • 6.1 Introduction
  • 6.2 Cholinesterase Inhibitors
  • 6.3 Monoclonal Antibodies
  • 6.4 Corticosteroids
  • 6.5 Immunosuppressants
  • 6.6 Intravenous Immunoglobulins
  • 6.7 Other Drug Classes

7 Global Myasthenia Gravis Disease Treatment Market, By Treatment Modality

  • 7.1 Introduction
  • 7.2 Surgery
  • 7.3 Intravenous Therapy
  • 7.4 Other Treatment Modalities

8 Global Myasthenia Gravis Disease Treatment Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Online Pharmacies
  • 8.3 Hospital Pharmacies
  • 8.4 Retail Pharmacies
  • 8.5 Other Distribution Channels

9 Global Myasthenia Gravis Disease Treatment Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Drug Class Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 AbbVie Inc.
  • 11.2 Alexion Pharmaceutical Inc.
  • 11.3 Amyasthenia gravisen inc.
  • 11.4 Astellas pharma inc.
  • 11.5 Astrazeneca
  • 11.6 Avadel Pharmaceuticals plc
  • 11.7 Bausch Health Companies Inc.
  • 11.8 Baxter International, Inc.
  • 11.9 Bayer ag
  • 11.10 Biogen
  • 11.11 Bristol-myers squibb
  • 11.12 CSL Behring
  • 11.13 Daiichi sankyo co. Ltd.
  • 11.14 F. Hoffmann-La Roche Ltd.
  • 11.15 Gilead sciences inc.
  • 11.16 Glaxosmithkline plc.
  • 11.17 Grifols SA
  • 11.18 Merck & co. Inc.
  • 11.19 Novartis AG
  • 11.20 Pfizer, Inc.
  • 11.21 Sanofi
  • 11.22 Servier laboratories
  • 11.23 Shire plc
  • 11.24 Takeda Pharmaceutical Company Limited
  • 11.25 Teva pharmaceutical industries ltd.
  • 11.26 Valeant Pharmaceuticals International, Inc.

List of Tables

  • Table 1 Global Myasthenia Gravis Disease Treatment Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Myasthenia Gravis Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Myasthenia Gravis Disease Treatment Market Outlook, By Generalized Myasthenia Gravis (2021-2030) ($MN)
  • Table 4 Global Myasthenia Gravis Disease Treatment Market Outlook, By Ocular Myasthenia Gravis (2021-2030) ($MN)
  • Table 5 Global Myasthenia Gravis Disease Treatment Market Outlook, By Transient Neonatal Myasthenia Gravis (2021-2030) ($MN)
  • Table 6 Global Myasthenia Gravis Disease Treatment Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 7 Global Myasthenia Gravis Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 8 Global Myasthenia Gravis Disease Treatment Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
  • Table 9 Global Myasthenia Gravis Disease Treatment Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 10 Global Myasthenia Gravis Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 11 Global Myasthenia Gravis Disease Treatment Market Outlook, By Immunosuppressants (2021-2030) ($MN)
  • Table 12 Global Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Immunoglobulins (2021-2030) ($MN)
  • Table 13 Global Myasthenia Gravis Disease Treatment Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 14 Global Myasthenia Gravis Disease Treatment Market Outlook, By Treatment Modality (2021-2030) ($MN)
  • Table 15 Global Myasthenia Gravis Disease Treatment Market Outlook, By Surgery (2021-2030) ($MN)
  • Table 16 Global Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Therapy (2021-2030) ($MN)
  • Table 17 Global Myasthenia Gravis Disease Treatment Market Outlook, By Other Treatment Modalities (2021-2030) ($MN)
  • Table 18 Global Myasthenia Gravis Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 19 Global Myasthenia Gravis Disease Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 20 Global Myasthenia Gravis Disease Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 21 Global Myasthenia Gravis Disease Treatment Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 22 Global Myasthenia Gravis Disease Treatment Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 23 North America Myasthenia Gravis Disease Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 24 North America Myasthenia Gravis Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 25 North America Myasthenia Gravis Disease Treatment Market Outlook, By Generalized Myasthenia Gravis (2021-2030) ($MN)
  • Table 26 North America Myasthenia Gravis Disease Treatment Market Outlook, By Ocular Myasthenia Gravis (2021-2030) ($MN)
  • Table 27 North America Myasthenia Gravis Disease Treatment Market Outlook, By Transient Neonatal Myasthenia Gravis (2021-2030) ($MN)
  • Table 28 North America Myasthenia Gravis Disease Treatment Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 29 North America Myasthenia Gravis Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 30 North America Myasthenia Gravis Disease Treatment Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
  • Table 31 North America Myasthenia Gravis Disease Treatment Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 32 North America Myasthenia Gravis Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 33 North America Myasthenia Gravis Disease Treatment Market Outlook, By Immunosuppressants (2021-2030) ($MN)
  • Table 34 North America Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Immunoglobulins (2021-2030) ($MN)
  • Table 35 North America Myasthenia Gravis Disease Treatment Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 36 North America Myasthenia Gravis Disease Treatment Market Outlook, By Treatment Modality (2021-2030) ($MN)
  • Table 37 North America Myasthenia Gravis Disease Treatment Market Outlook, By Surgery (2021-2030) ($MN)
  • Table 38 North America Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Therapy (2021-2030) ($MN)
  • Table 39 North America Myasthenia Gravis Disease Treatment Market Outlook, By Other Treatment Modalities (2021-2030) ($MN)
  • Table 40 North America Myasthenia Gravis Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 41 North America Myasthenia Gravis Disease Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 42 North America Myasthenia Gravis Disease Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 43 North America Myasthenia Gravis Disease Treatment Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 44 North America Myasthenia Gravis Disease Treatment Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 45 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 46 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 47 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Generalized Myasthenia Gravis (2021-2030) ($MN)
  • Table 48 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Ocular Myasthenia Gravis (2021-2030) ($MN)
  • Table 49 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Transient Neonatal Myasthenia Gravis (2021-2030) ($MN)
  • Table 50 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 51 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 52 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
  • Table 53 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 54 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 55 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Immunosuppressants (2021-2030) ($MN)
  • Table 56 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Immunoglobulins (2021-2030) ($MN)
  • Table 57 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 58 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Treatment Modality (2021-2030) ($MN)
  • Table 59 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Surgery (2021-2030) ($MN)
  • Table 60 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Therapy (2021-2030) ($MN)
  • Table 61 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Other Treatment Modalities (2021-2030) ($MN)
  • Table 62 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 63 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 64 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 65 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 66 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 67 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 68 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 69 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Generalized Myasthenia Gravis (2021-2030) ($MN)
  • Table 70 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Ocular Myasthenia Gravis (2021-2030) ($MN)
  • Table 71 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Transient Neonatal Myasthenia Gravis (2021-2030) ($MN)
  • Table 72 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 73 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 74 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
  • Table 75 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 76 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 77 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Immunosuppressants (2021-2030) ($MN)
  • Table 78 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Immunoglobulins (2021-2030) ($MN)
  • Table 79 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 80 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Treatment Modality (2021-2030) ($MN)
  • Table 81 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Surgery (2021-2030) ($MN)
  • Table 82 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Therapy (2021-2030) ($MN)
  • Table 83 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Other Treatment Modalities (2021-2030) ($MN)
  • Table 84 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 85 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 86 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 87 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 88 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 89 South America Myasthenia Gravis Disease Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 90 South America Myasthenia Gravis Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 91 South America Myasthenia Gravis Disease Treatment Market Outlook, By Generalized Myasthenia Gravis (2021-2030) ($MN)
  • Table 92 South America Myasthenia Gravis Disease Treatment Market Outlook, By Ocular Myasthenia Gravis (2021-2030) ($MN)
  • Table 93 South America Myasthenia Gravis Disease Treatment Market Outlook, By Transient Neonatal Myasthenia Gravis (2021-2030) ($MN)
  • Table 94 South America Myasthenia Gravis Disease Treatment Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 95 South America Myasthenia Gravis Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 96 South America Myasthenia Gravis Disease Treatment Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
  • Table 97 South America Myasthenia Gravis Disease Treatment Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 98 South America Myasthenia Gravis Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 99 South America Myasthenia Gravis Disease Treatment Market Outlook, By Immunosuppressants (2021-2030) ($MN)
  • Table 100 South America Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Immunoglobulins (2021-2030) ($MN)
  • Table 101 South America Myasthenia Gravis Disease Treatment Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 102 South America Myasthenia Gravis Disease Treatment Market Outlook, By Treatment Modality (2021-2030) ($MN)
  • Table 103 South America Myasthenia Gravis Disease Treatment Market Outlook, By Surgery (2021-2030) ($MN)
  • Table 104 South America Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Therapy (2021-2030) ($MN)
  • Table 105 South America Myasthenia Gravis Disease Treatment Market Outlook, By Other Treatment Modalities (2021-2030) ($MN)
  • Table 106 South America Myasthenia Gravis Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 107 South America Myasthenia Gravis Disease Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 108 South America Myasthenia Gravis Disease Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 109 South America Myasthenia Gravis Disease Treatment Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 110 South America Myasthenia Gravis Disease Treatment Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 111 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 112 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 113 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Generalized Myasthenia Gravis (2021-2030) ($MN)
  • Table 114 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Ocular Myasthenia Gravis (2021-2030) ($MN)
  • Table 115 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Transient Neonatal Myasthenia Gravis (2021-2030) ($MN)
  • Table 116 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 117 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 118 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
  • Table 119 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 120 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 121 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Immunosuppressants (2021-2030) ($MN)
  • Table 122 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Immunoglobulins (2021-2030) ($MN)
  • Table 123 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 124 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Treatment Modality (2021-2030) ($MN)
  • Table 125 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Surgery (2021-2030) ($MN)
  • Table 126 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Therapy (2021-2030) ($MN)
  • Table 127 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Other Treatment Modalities (2021-2030) ($MN)
  • Table 128 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 129 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 130 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 131 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 132 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Other Distribution Channels (2021-2030) ($MN)